Nifty
:
15847.60
Sensex
:
52851.69
-392.70 (-2.42%)
-1356.84 (-2.50%)
Nifty
Sensex
:
:
15847.60
52851.69
-392.70 (-2.42%)
-1356.84 (-2.50%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
60/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
899.15
18-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  891.00
  •  909.00
  •  888.00
  •  891.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2878378
  •  25969.15
  •  967.05
  •  652.70

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 215,796.19
  • 33.47
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 213,219.26
  • 0.83%
  • 4.17

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.94%
  • 6.49%
  • FII
  • DII
  • Others
  • 14.44%
  • 19.57%
  • 2.08%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.37
  • 1.36
  • 4.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.28
  • -2.64
  • 6.18

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.93
  • -15.96
  • 3.02

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 35.62
  • 34.68
  • 33.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.50
  • 3.15
  • 3.07

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.88
  • 16.32
  • 16.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Net Sales
9,863.06
8,836.78
11.61%
9,625.93
8,553.13
12.54%
9,718.74
7,585.25
28.13%
8,522.98
8,184.94
4.13%
Expenses
7,256.73
6,502.27
11.60%
6,995.99
6,359.85
10.00%
6,977.54
5,820.90
19.87%
6,474.54
6,821.93
-5.09%
EBITDA
2,606.33
2,334.51
11.64%
2,629.94
2,193.28
19.91%
2,741.20
1,764.35
55.37%
2,048.44
1,363.01
50.29%
EBIDTM
26.43%
26.42%
27.32%
25.64%
28.21%
23.26%
24.03%
16.65%
Other Income
432.51
386.58
11.88%
222.89
255.78
-12.86%
232.40
232.95
-0.24%
111.00
102.23
8.58%
Interest
18.97
26.10
-27.32%
35.95
33.28
8.02%
35.09
51.95
-32.45%
30.10
51.78
-41.87%
Depreciation
553.68
531.94
4.09%
530.37
498.60
6.37%
503.22
495.92
1.47%
553.49
575.38
-3.80%
PBT
2,466.19
2,163.05
14.01%
2,286.51
1,917.18
19.26%
1,804.22
-2,183.90
-
903.04
577.44
56.39%
Tax
335.39
244.94
36.93%
197.78
-31.20
-
395.57
245.91
60.86%
55.04
83.09
-33.76%
PAT
2,130.80
1,918.11
11.09%
2,088.73
1,948.38
7.20%
1,408.65
-2,429.81
-
848.00
494.35
71.54%
PATM
21.60%
21.71%
21.70%
22.78%
14.49%
-32.03%
9.95%
6.04%
EPS
8.58
7.72
11.14%
8.53
7.56
12.83%
6.02
-6.90
-
3.73
1.67
123.35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
37,730.71
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
27,392.01
16,080.36
11,299.86
8,019.49
Net Sales Growth
13.78%
2.01%
12.98%
10.03%
-15.63%
11.38%
2.62%
70.34%
42.31%
40.90%
 
Cost Of Goods Sold
10,052.67
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
6,732.84
2,777.68
2,076.36
1,647.61
Gross Profit
27,678.04
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
20,659.17
13,302.68
9,223.50
6,371.88
GP Margin
73.36%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
75.42%
82.73%
81.62%
79.45%
Total Expenditure
27,704.80
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
19,615.54
9,120.95
6,437.76
4,836.43
Power & Fuel Cost
-
627.09
621.89
613.60
559.97
525.09
545.44
560.77
232.41
187.10
145.65
% Of Sales
-
1.87%
1.89%
2.11%
2.12%
1.68%
1.94%
2.05%
1.45%
1.66%
1.82%
Employee Cost
-
6,862.23
6,362.35
5,967.09
5,367.05
4,902.30
4,772.31
4,502.64
2,074.44
1,534.53
1,187.73
% Of Sales
-
20.49%
19.38%
20.53%
20.32%
15.66%
16.98%
16.44%
12.90%
13.58%
14.81%
Manufacturing Exp.
-
1,723.78
1,690.00
1,884.71
1,827.40
1,293.98
1,418.59
1,433.89
815.49
618.43
462.65
% Of Sales
-
5.15%
5.15%
6.48%
6.92%
4.13%
5.05%
5.23%
5.07%
5.47%
5.77%
General & Admin Exp.
-
3,179.45
3,340.89
2,729.20
2,862.45
3,113.67
2,956.85
2,894.97
978.48
793.38
629.48
% Of Sales
-
9.49%
10.17%
9.39%
10.84%
9.95%
10.52%
10.57%
6.08%
7.02%
7.85%
Selling & Distn. Exp.
-
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
2,236.40
1,394.78
763.01
516.55
% Of Sales
-
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
8.16%
8.67%
6.75%
6.44%
Miscellaneous Exp.
-
843.83
963.29
1,107.57
1,047.60
1,106.04
1,824.56
1,254.03
847.67
464.95
516.55
% Of Sales
-
2.52%
2.93%
3.81%
3.97%
3.53%
6.49%
4.58%
5.27%
4.11%
3.08%
EBITDA
10,025.91
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
7,776.47
6,959.41
4,862.10
3,183.06
EBITDA Margin
26.57%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
28.39%
43.28%
43.03%
39.69%
Other Income
998.80
859.17
651.59
1,059.44
912.08
1,030.20
658.25
637.89
592.59
422.23
492.77
Interest
120.11
141.43
302.73
555.25
517.57
399.80
523.24
578.99
44.19
43.16
28.20
Depreciation
2,140.76
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
1,194.72
409.23
336.17
291.16
PBT
7,459.96
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
6,640.65
7,098.58
4,905.00
3,356.47
Tax
983.78
514.69
822.80
600.88
911.04
1,211.57
913.77
914.69
702.17
845.55
313.19
Tax Rate
13.19%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
14.29%
15.33%
19.57%
9.33%
PAT
6,476.18
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
4,551.94
3,141.47
2,989.59
2,657.80
PAT before Minority Interest
6,461.24
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
5,488.21
3,879.00
3,475.87
3,043.28
Minority Interest
-14.94
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
-936.27
-737.53
-486.28
-385.48
PAT Margin
17.16%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
16.62%
19.54%
26.46%
33.14%
PAT Growth
235.37%
-22.85%
41.73%
25.73%
-69.50%
53.04%
-0.17%
44.90%
5.08%
12.48%
 
EPS
26.99
12.15
15.75
11.12
8.84
28.99
18.94
18.97
13.09
12.46
11.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
25,638.09
18,524.95
14,989.73
12,235.78
Share Capital
239.93
239.93
239.93
239.93
239.93
240.66
207.12
207.12
103.56
103.56
Total Reserves
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
25,374.38
18,317.83
14,886.17
12,132.22
Non-Current Liabilities
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
2,335.46
1,748.41
199.02
-225.23
Secured Loans
7.83
6.18
109.47
217.69
185.59
7.73
40.69
43.76
41.90
49.65
Unsecured Loans
890.30
2,022.74
1,413.14
1,554.40
1,250.49
3,102.57
1,327.73
4.91
73.36
105.77
Long Term Provisions
327.12
511.00
430.39
404.46
1,211.11
1,895.86
2,532.34
2,601.62
787.06
138.73
Current Liabilities
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
16,146.81
5,989.59
2,841.25
2,618.49
Trade Payables
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
3,286.54
1,328.26
1,057.99
992.72
Other Current Liabilities
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
2,279.59
260.41
218.65
363.66
Short Term Borrowings
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
6,227.92
2,440.34
82.95
109.57
Short Term Provisions
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
4,352.76
1,960.58
1,481.66
1,152.54
Total Liabilities
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49
Net Block
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
12,682.47
6,817.28
5,647.47
3,951.35
Gross Block
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
20,406.89
10,485.12
8,709.22
6,448.66
Accumulated Depreciation
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
7,724.42
3,667.84
3,061.75
2,497.31
Non Current Assets
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
18,055.80
9,497.56
8,161.89
5,496.96
Capital Work in Progress
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
2,038.61
841.54
562.61
344.65
Non Current Investment
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
598.87
787.56
1,106.35
588.96
Long Term Loans & Adv.
4,061.34
4,104.48
3,848.29
6,052.85
3,844.04
2,322.87
2,631.91
1,016.98
802.56
593.29
Other Non Current Assets
4.67
5.53
21.96
50.21
682.18
953.34
103.94
34.20
42.90
18.71
Current Assets
30,442.08
31,654.16
31,069.19
31,635.90
32,953.65
29,941.30
28,915.75
18,686.46
11,503.03
10,293.37
Current Investments
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
2,117.43
1,998.46
1,305.22
1,623.91
Inventories
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
5,667.99
3,123.01
2,577.76
2,086.98
Sundry Debtors
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
5,106.13
2,200.42
2,412.23
2,078.74
Cash & Bank
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
10,998.04
7,590.15
4,058.71
3,367.19
Other Current Assets
2,808.09
1,541.48
1,266.30
891.31
3,546.51
2,847.64
5,026.16
3,774.42
1,149.11
1,136.55
Short Term Loans & Adv.
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
1,920.52
1,093.74
952.93
976.71
Net Current Assets
14,296.45
15,947.73
13,729.57
11,771.58
15,066.63
16,797.34
12,768.94
12,696.87
8,661.78
7,674.88
Total Assets
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
46,971.55
28,184.13
19,665.08
15,790.49

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
5,615.74
3,959.20
3,356.58
2,234.46
PBT
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
6,402.90
4,581.17
4,314.89
3,355.36
Adjustment
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
773.61
-40.15
160.00
111.12
Changes in Working Capital
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
179.59
207.10
-44.83
-1,005.25
Cash after chg. in Working capital
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
7,356.10
4,748.12
4,430.06
2,461.23
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
-1,740.36
-788.92
-1,073.48
-226.77
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
-2,865.74
-2,366.76
-2,635.05
-862.71
Net Fixed Assets
-697.67
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
-4,631.67
-380.81
-341.28
-267.49
Net Investments
363.04
542.39
451.15
978.04
3,038.39
3,504.47
-18,860.43
-2,698.19
120.24
-836.36
Others
870.85
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
20,626.36
712.24
-2,414.01
241.14
Cash from Financing Activity
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
-1,186.53
506.57
-664.99
-544.39
Net Cash Inflow / Outflow
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
1,563.47
2,099.01
56.54
827.36
Opening Cash & Equivalents
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
4,358.70
2,069.11
1,752.67
810.49
Closing Cash & Equivalent
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,285.56
4,358.70
2,069.11
1,752.67

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
193.65
188.66
172.59
159.69
152.70
137.03
123.49
89.44
72.37
59.08
ROA
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
14.60%
16.21%
19.61%
22.00%
ROE
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
24.89%
23.15%
25.53%
28.02%
ROCE
5.66%
10.07%
8.68%
8.40%
0.00%
18.64%
25.06%
25.46%
31.39%
30.13%
Fixed Asset Turnover
1.74
1.78
1.92
1.99
1.29
1.34
1.79
1.70
1.51
1.38
Receivable days
54.88
56.22
54.10
53.53
83.25
76.12
48.20
51.72
71.46
71.49
Inventory Days
50.10
48.40
47.84
48.88
78.98
77.46
57.99
63.92
74.22
80.31
Payable days
158.71
152.86
77.81
90.19
85.47
75.24
52.05
56.33
65.15
64.51
Cash Conversion Cycle
-53.73
-48.24
24.13
12.23
76.75
78.34
54.14
59.31
80.53
87.29
Total Debt/Equity
0.08
0.18
0.25
0.27
0.27
0.26
0.35
0.14
0.02
0.03
Interest Cover
20.79
17.55
7.86
7.72
23.63
13.56
12.06
104.67
101.13
120.02

Annual Reports:

FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013
FY 2012

News Update:


  • Sun Pharma to launch Brillo
    18th May 2022, 16:58 PM

    Brillo is a first-in-class drug which has a new mechanism of action compared to the currently available lipid-lowering agents

    Read More
  • Sun Pharma gets USFDA nod for generic Mesalamine extended release capsules
    12th May 2022, 18:02 PM

    Pentasa Extended Release Capsules, 500mg had annualized sales of approximately $213 million in USA

    Read More
  • USFDA conducts GMP inspection at Sun Pharma’s Halol facility
    10th May 2022, 12:00 PM

    At the conclusion of the inspection, the USFDA issued a Form-483, with 10 observations

    Read More
  • Sun Pharma inks pact with Lundbeck to market, distribute Vortioxetine in India
    30th Mar 2022, 14:49 PM

    The territory of the licensing agreement will only cover India

    Read More
  • Sun Pharmaceutical Industries, Ranbaxy sign pact with 2 plaintiff groups to settle claims
    24th Mar 2022, 10:45 AM

    The case has been ongoing in the U.S. District Court for the District of Massachusetts (USA) for several years

    Read More
  • Sun Pharma inks pact to pick up 11.28% stake in Zenotech from Daiichi Sankyo
    22nd Mar 2022, 12:17 PM

    The primary objective of the transaction from acquirer's perspective is to consolidate its holding in the target company

    Read More
  • Sun Pharma’s arm recalls Chlorthalidone tablets in US market
    28th Feb 2022, 10:00 AM

    The company initiated the Class II voluntary recall on February 7, 2022

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.